
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Holdings Inc. has demonstrated promising advancements in its lead therapy, detalimogene, which has shown a six-month complete response (CR) rate comparable to leading treatments within the non-muscle invasive bladder cancer (NMIBC) space while benefiting from a non-viral delivery method that enhances safety and ease of use. The company's recent protocol amendments significantly improved CR rates, exceeding previous investor expectations and aligning with best-in-class therapies, which strengthens the potential for adoption among urologists for patients unresponsive to traditional treatments. Furthermore, with an updated discounted cash flow (DCF) analysis forecasting increased sales to $530 million by 2031, enGene Holdings highlights a strong growth trajectory, bolstered by the favorable clinical profile and rising conviction among healthcare professionals.
Bears say
enGene Holdings Inc. is facing significant challenges that negatively impact its stock outlook, primarily due to disappointing performance in the ongoing LEGEND trial, with observed complete response (CR) rates significantly lower than initially anticipated. Unexpected safety issues and changes in regulatory requirements for non-muscle invasive bladder cancer (NMIBC) approvals add further uncertainty to the company's potential for successful drug development. Additionally, the anticipated need for higher capital, potentially leading to increased equity dilution, poses financial risks that could undermine shareholder value.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares